2-[18F]Fludarabine, a Novel Positron Emission Tomography (PET) Tracer for Imaging Lymphoma: a Micro-PET Study in Murine Models

被引：11

作者：

Dhilly, Martine ^{[1
,2
,3
]}

Guillouet, Stephane ^{[1
,2
,3
]}

Patin, Delphine ^{[1
,2
,3
]}

Fillesoye, Fabien ^{[1
,2
,3
]}

Abbas, Ahmed ^{[2
,5
]}

Gourand, Fabienne ^{[1
,2
,3
]}

Tirel, Olivier ^{[1
,2
,3
]}

Galateau, Francoise ^{[6
]}

MacKenzie, Eric T. ^{[2
,4
]}

Dumontet, Charles ^{[7
]}

Leporrier, Michel ^{[1
,2
,3
]}

Barre, Louisa ^{[1
,2
,3
]}

机构：

[1] GIP Cyceron, CEA, DSV I2BM, LDM TEP Grp, F-14074 Caen, France

[2] Univ Caen Basse Normandie, Caen, France

[3] GIP Cyceron, CNRS, UMR ISTCT 6301, LDM TEP Grp, F-14074 Caen, France

[4] CERVOxy Grp, CNRS, UMR ISTCT 6301, Caen, France

[5] GIP Cyceron, INSERM, U1077, F-14074 Caen, France

[6] CHU Caen, Serv Anat Pathol, F-14033 Caen, France

[7] Univ Lyon, Hosp Civils Lyon, CNRS 5286, CRCL,INSERM 1052, F-69008 Lyon, France

来源：

MOLECULAR IMAGING AND BIOLOGY | 2014年 / 16卷 / 01期

关键词：

2-[F-18]Fludarabine; PET; Imaging; Lymphoma; CHRONIC LYMPHOCYTIC-LEUKEMIA; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; RESPONSE ASSESSMENT; FOLLOW-UP; 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE; PHARMACOKINETICS; F-18-FDG-PET; RESISTANT; SURVIVAL;

D O I：

10.1007/s11307-013-0659-2

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Fludarabine has proven to be of considerable efficacy in the treatment of low-grade lymphomas. We have developed the labeling of this drug with fluorine-18 and evaluated 2-[F-18]fludarabine as a novel positron emission tomography (PET) probe for in vivo imaging. Preclinical studies were conducted with 2-[F-18]fludarabine, in parallel with 2-deoxy-2-[F-18]fluoro-d-glucose ([F-18]FDG), in Swiss CD-1 and CB17 severely combined immunodeficient (SCID) mice, both as tumor-free control groups, and SCID mice bearing RL lymphomas. In Swiss mice, micro-PET studies with 2-[F-18]fludarabine showed a distribution restricted to the organs of excretion and the spleen, the latter being less evident in SCID animals. In lymphoma-bearing SCID mice, 2-[F-18]fludarabine demonstrated a rapid tumor uptake over the first 20 min which subsequently plateaued and provided an improved contrast than that of [F-18]FDG. This radiotracer merits further evaluation to establish its clinical usefulness to image low-grade lymphoma in humans in future clinical investigations.

引用

页码：118 / 126

页数：9

共 30 条

[1] Performance Evaluation of the Inveon Dedicated PET Preclinical Tomograph Based on the NEMA NU-4 Standards [J].

Bao, Qinan ;

Newport, Danny ;

Chen, Mu ;

Stout, David B. ;

Chatziioannou, Arion F. .

JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (03) :401-408

[2]

BARRUECO JR, 1987, CANCER RES, V47, P700

[3] Molecular Imaging of proliferation in malignant lymphoma [J].

Buck, Andreas K. ;

Bommer, Martin ;

Stilgenbauer, Stephan ;

Juweid, Malik ;

Glatting, Gerhard ;

Schirrmeister, Holger ;

Mattfeldt, Torsten ;

Tepsic, Djurdja ;

Bunjes, Donald ;

Mottaghy, Felix M. ;

Krause, Bernd J. ;

Neumaier, Bernd ;

Doehner, Hartmut ;

Moeller, Peter ;

Reske, Sven N. .

CANCER RESEARCH, 2006, 66 (22) :11055-11061

[4] Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 [J].

Byrd, JC ;

Rai, K ;

Peterson, BL ;

Appelbaum, FR ;

Morrison, VA ;

Kolitz, JE ;

Shepherd, L ;

Hines, JD ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2005, 105 (01) :49-53

[5] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[6] In vivo Model of Follicular Lymphoma Resistant to Rituximab [J].

Dalle, Stephane ;

Dupire, Sophie ;

Brunet-Manquat, Stephanie ;

Reslan, Lina ;

Plesa, Adriana ;

Dumontet, Charles .

CLINICAL CANCER RESEARCH, 2009, 15 (03) :851-857

[7]

DANHAUSER L, 1986, CANCER CHEMOTH PHARM, V18, P145

[8] Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging [J].

Deloar, HM ;

Fujiwara, T ;

Shidahara, M ;

Nakamura, T ;

Watabe, H ;

Narita, Y ;

Itoh, M ;

Miyake, M ;

Watanuki, S .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (06) :565-574

[9] Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia [J].

Eichhorst, BF ;

Busch, R ;

Hopfinger, G ;

Pasold, R ;

Hensel, M ;

Steinbrecher, C ;

Siehl, S ;

Jäger, U ;

Bergmann, M ;

Stilgenbauer, S ;

Schweighofer, C ;

Wendtner, CM ;

Döhner, H ;

Brittinger, G ;

Emmerich, B ;

Hallek, M .

BLOOD, 2006, 107 (03) :885-891

[10] PET positive, PET negative, or PET peeve? [J].

Friedberg, Jonathan W. .

BLOOD, 2010, 115 (04) :752-753

← 1 2 3 →